Abeona Therapeutics Q3 2025: Strong Financials And Zevaskyn Launch Ahead [Seeking Alpha]
Abeona Therapeutics Inc. (ABEO)
Last abeona therapeutics inc. earnings: 3/16 04:20 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.abeonatherapeutics.com
Company Research
Source: Seeking Alpha
Zevaskyn's commercial launch is delayed to 4Q25 due to FDA assay requirements, but demand and payer coverage remain robust, aided by a new CMS J-code. ABEO's financials improved significantly, with reduced R&D expenses and a strengthened balance sheet, positioning the company well for commercialization. Despite a 22% stock jump, ABEO's valuation remains attractive, with revenue potential from Zevaskyn and sector re-rating likely as commercialization progresses. Miyako Nakamura/E+ via Getty Images Thesis Abeona Therapeutics Inc. ( ABEO ) reported some pretty attractive figures for 3Q25, and the stock is already up 22% post announcement. GAAP EPS came in at just -$0.10, beating expectations by $0.18. The company also ended the quarter with This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article my
Show less
Read more
Impact Snapshot
Event Time:
ABEO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABEO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABEO alerts
High impacting Abeona Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
ABEO
News
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]Yahoo! Finance
- Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswire
- Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business Officer [Yahoo! Finance]Yahoo! Finance
- Abeona Therapeutics® Announces Appointment of Mohamad Tabrizi as Chief Business OfficerGlobeNewswire
- Abeona Therapeutics® Announces New Qualified Treatment Center for ZEVASKYN® in TexasGlobeNewswire
ABEO
Earnings
- 11/12/25 - Beat
ABEO
Sec Filings
- 2/4/26 - Form 4
- 2/2/26 - Form 4
- 2/2/26 - Form 4
- ABEO's page on the SEC website